Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
about
Clinical significance of HIV-1 coreceptor usage.Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossReplicative capacity of human immunodeficiency virus type 1 transmitted from mother to child is associated with pediatric disease progression rateMode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.The role of genetic variants of Stromal cell-Derived Factor 1 in pediatric HIV-1 infection and disease progression.Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression.An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype BIndependent evolution of macrophage-tropism and increased charge between HIV-1 R5 envelopes present in brain and immune tissue.Oral CCR5 inhibitors: will they make it through?Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques.Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma virusesEvolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression.Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection.HIV-1 envelope replication and α4β7 utilization among newly infected subjects and their corresponding heterosexual partners.Identification of Emerging Macrophage-Tropic HIV-1 R5 Variants in Brain Tissue of AIDS Patients without Severe Neurological Complications.Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivityVariation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.Human immunodeficiency virus type 1 biological variation and coreceptor use: from concept to clinical significance.An allosteric rheostat in HIV-1 gp120 reduces CCR5 stoichiometry required for membrane fusion and overcomes diverse entry limitations.Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers.Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency.
P2860
Q27691426-4B3188E0-3266-4E43-8190-0A16A5F03519Q28469223-3533D409-EB69-44CC-A808-E51568842B97Q33558599-E6CEBA68-91C7-4B45-AC9E-609078ABC276Q33686847-58D54311-8E63-4BC8-8B84-886127D7D6E6Q33807529-B9B028ED-A966-474D-9050-84E5949ACCA6Q33941033-256D5275-654B-4806-932B-A764BCA2BBC6Q33961448-D621A0C8-101E-47FC-AA9E-E173FC4F5C18Q34008699-607DB575-8009-47C5-978B-A5A9A817F4F3Q34170655-CB66AB9C-52BA-4616-B967-58FA4CB8CAC6Q34409877-91B8E297-5AD7-4744-B20D-702F389221AFQ34425169-2909E7BC-1ADE-4E49-AD7A-D63D09C36639Q34569382-B6E0634B-87CD-4F8B-AD5C-358441133605Q34757951-D73CA5AD-0EC0-45A2-827A-E10380842F18Q34806205-1D4ED65B-0F0D-460B-A578-25D87D763BF6Q34987062-E0950FA2-7E00-4875-94AC-109D6655F683Q35140461-C0EB92BA-1C81-4A00-A014-AC934F33FF04Q35364051-F3234F66-3800-4414-8D13-5B797BE41C4AQ35996364-B99C0A7E-2EC2-4E4C-8969-F9516676F22DQ36458354-F79C709F-00D3-4B62-87F1-830C8836A92CQ36484034-9096E093-0632-4246-B303-6AF707FED6DAQ36502557-8403AD9A-7C88-4FCB-B918-1265910807E1Q36580487-84D47CE8-4969-4DA9-B24C-DE520B60A1E7Q37356028-E4F13198-6A40-44EC-8A8D-4D8608810A18Q37444204-86701AC9-0AE2-48E1-A982-1A50F68D3DD1Q38645990-61166FB4-0D0F-4FA4-8863-BBECC28002E7Q38703060-6925458A-F417-4701-863D-B094E3FBD1B4Q39186710-9EC795FA-B955-4D8B-A6C9-9D177ECFB9C9Q39351549-6B5D6BAB-65E6-42B7-8CA0-80C8AAC6F6CAQ39471859-4FF0BE3B-B5F6-4817-AB73-F9FFFAFDF73CQ41996301-AA1292BB-47E6-41D1-AE8E-2C4F998831EBQ42348438-AA1840D0-B915-4E7C-9A9A-86ACEDD6FB3DQ42600049-A15D1757-4479-4C11-8229-CFA10A1981E2
P2860
Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Selection of human immunodefic ...... uring severe immunodeficiency.
@en
Selection of human immunodefic ...... uring severe immunodeficiency.
@nl
type
label
Selection of human immunodefic ...... uring severe immunodeficiency.
@en
Selection of human immunodefic ...... uring severe immunodeficiency.
@nl
prefLabel
Selection of human immunodefic ...... uring severe immunodeficiency.
@en
Selection of human immunodefic ...... uring severe immunodeficiency.
@nl
P2093
P50
P356
P1476
Selection of human immunodefic ...... during severe immunodeficiency
@en
P2093
Anders Karlsson
Jan Albert
Johanna Repits
Monica Oberg
Patrik Medstrand
P304
P356
10.1099/VIR.0.81111-0
P407
P577
2005-10-01T00:00:00Z